-

NYSE American to Commence Delisting Proceedings Against Viveon Health Acquisition Corp. (VHAQ)

NEW YORK--(BUSINESS WIRE)--NYSE American LLC (“NYSE American” or the “Exchange”) announced today that the staff of NYSE Regulation has determined to commence proceedings to delist the three securities enumerated below (“Securities”) of Viveon Health Acquisition Corp. (the “Company”) from NYSE American.

Symbol

Description

VHAQ

Common Stock

VHAQU

Units

VHAQR

Rights

NYSE Regulation reached its decision to delist the Company’s Securities pursuant to Sections 119(b) and 119(f) of the NYSE American Company Guide because the Company failed to consummate a business combination (i) within 36 months of the effectiveness of its initial public offering registration statement, or (ii) such shorter period that the Company specified in its registration statement.

The Company has a right to a review of NYSE Regulation staff’s determination to delist the common stock by the Listings Qualifications Panel of the Committee for Review of the Board of Directors of the Exchange (the “Panel”). Following such appeal and a decision by the Panel, NYSE American or the Company will make an announcement regarding either proceeding with suspension and delisting or continued trading in the Company’s common stock. If the Company does not appeal this determination, NYSE American will announce the date that trading will be suspended. The filing of an application with the Securities and Exchange Commission to delist the common stock is pending completion of all applicable procedures, including any appeal by the Company of the NYSE Regulation staff’s decision.

Contacts

Company Contact:
Rom Papadopoulos, M.D.
Chief Financial Officer
T (404) 861-5393
E rom@viveonhealth.com

NYSE Contact:
NYSE Communications
PublicRelations-NYSE@ice.com

NYSE Regulation


Release Versions

Contacts

Company Contact:
Rom Papadopoulos, M.D.
Chief Financial Officer
T (404) 861-5393
E rom@viveonhealth.com

NYSE Contact:
NYSE Communications
PublicRelations-NYSE@ice.com

More News From NYSE Regulation

NYSE to Commence Delisting Proceedings Against Vicarious Surgical Inc. (RBOT)

NEW YORK--(BUSINESS WIRE)--The New York Stock Exchange (“NYSE”, the “Exchange”) announced today that the staff of NYSE Regulation has determined to commence proceedings to delist the Class A common stock of Vicarious Surgical Inc. (the “Company”) — ticker symbol RBOT — from the NYSE. Trading in the Company’s Class A common stock will be suspended immediately. NYSE Regulation reached its decision to delist the Company’s Class A common stock pursuant to Section 802.01B of the NYSE’s Listed Compan...

NYSE to Commence Delisting Proceedings Against Trinseo PLC (TSE)

NEW YORK--(BUSINESS WIRE)--The New York Stock Exchange (“NYSE”, the “Exchange”) announced today that the staff of NYSE Regulation has determined to commence proceedings to delist the ordinary shares of Trinseo PLC (the “Company”) — ticker symbol TSE — from the NYSE. Trading in the Company’s ordinary shares will be suspended immediately. NYSE Regulation reached its decision to delist the Company’s ordinary shares pursuant to Section 802.01B of the NYSE’s Listed Company Manual because the Company...

NYSE to Commence Delisting Proceedings Against Allurion Technologies, Inc. (ALUR)

NEW YORK--(BUSINESS WIRE)--The New York Stock Exchange (“NYSE”, the “Exchange”) announced today that the staff of NYSE Regulation has determined to commence proceedings to delist the two securities enumerated below (“Securities”) of Allurion Technologies, Inc. (the “Company”) from the NYSE. Trading in these Securities will continue on the NYSE until such time as described below. Symbol Description ALUR Common stock, par value $0.0001 per share ALUR WS Warrants to purchase 0.056818 shares of com...
Back to Newsroom